HDAC9 and mantle cell lymphoma: Concerning outcomes, MCL patients treated with (R)-CHOP induction had a median OS of 26.5 months (95% CI: 18.5–34.4 months), while those receiving (R)-HDAC showed a median OS of 55.4 months (95% CI: 26.1–84.7 months).